Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide.
Moderate growth potential second-rate dividend payer.
Share Price & News
How has Becton Dickinson's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: BDX has not had significant price volatility in the past 3 months.
7 Day Return
US Medical Equipment
1 Year Return
US Medical Equipment
Return vs Industry: BDX underperformed the US Medical Equipment industry which returned 19.4% over the past year.
Return vs Market: BDX underperformed the US Market which returned 17.8% over the past year.
Price Volatility Vs. Market
How volatile is Becton Dickinson's share price compared to the market and industry in the last 5 years?
Simply Wall St News
5 days ago | Simply Wall StIs Becton, Dickinson and Company's (NYSE:BDX) ROE Of 4.3% Concerning?
2 weeks ago | Simply Wall StHave Insiders Sold Becton, Dickinson and Company (NYSE:BDX) Shares Recently?
3 weeks ago | Simply Wall StEstimating The Intrinsic Value Of Becton, Dickinson and Company (NYSE:BDX)
Is Becton Dickinson undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: BDX ($257.35) is trading below our estimate of fair value ($285.12)
Significantly Below Fair Value: BDX is trading below fair value, but not by a significant amount.
Price To Earnings Ratio
PE vs Industry: BDX is poor value based on its PE Ratio (91.6x) compared to the Medical Equipment industry average (46.6x).
PE vs Market: BDX is poor value based on its PE Ratio (91.6x) compared to the US market (18.2x).
Price to Earnings Growth Ratio
PEG Ratio: BDX is poor value based on its PEG Ratio (2.1x)
Price to Book Ratio
PB vs Industry: BDX is good value based on its PB Ratio (3.3x) compared to the US Medical Equipment industry average (4.1x).
How is Becton Dickinson forecast to perform in the next 1 to 3 years based on estimates from 16 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BDX's forecast earnings growth (43.5% per year) is above the savings rate (1.7%).
Earnings vs Market: BDX's earnings (43.5% per year) are forecast to grow faster than the US market (14.1% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: BDX's revenue (5% per year) is forecast to grow slower than the US market (7.6% per year).
High Growth Revenue: BDX's revenue (5% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: BDX's Return on Equity is forecast to be low in 3 years time (16.6%).
How has Becton Dickinson performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: BDX has a large one-off loss of $1.5B impacting its December 31 2019 financial results.
Growing Profit Margin: BDX's current net profit margins (4.4%) are lower than last year (5.2%).
Past Earnings Growth Analysis
Earnings Trend: BDX's earnings have declined by -7.6% per year over the past 5 years.
Accelerating Growth: BDX's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: BDX had negative earnings growth (-15%) over the past year, making it difficult to compare to the Medical Equipment industry average (1.7%).
Return on Equity
High ROE: BDX's Return on Equity (4.3%) is considered low.
Return on Assets
Return on Capital Employed
How is Becton Dickinson's financial position?
Financial Position Analysis
Short Term Liabilities: BDX's short term assets ($6.4B) do not cover its short term liabilities ($6.7B).
Long Term Liabilities: BDX's short term assets ($6.4B) do not cover its long term liabilities ($24.0B).
Debt to Equity History and Analysis
Debt Level: BDX's debt to equity ratio (91.5%) is considered high.
Reducing Debt: BDX's debt to equity ratio has reduced from 200% to 91.5% over the past 5 years.
Debt Coverage: BDX's debt is not well covered by operating cash flow (19.6%).
Interest Coverage: BDX's interest payments on its debt are well covered by EBIT (4.9x coverage).
Inventory Level: BDX has a low level of unsold assets or inventory.
Debt Coverage by Assets: BDX's debt is not covered by short term assets (assets are 0.3x debt).
What is Becton Dickinson's current dividend yield, its reliability and sustainability?
Current Dividend Yield
Upcoming Dividend Payment
Purchase Becton Dickinson before the 'Buy Limit' to receive their next dividend payment.
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: BDX's dividend (1.23%) isn’t notable compared to the bottom 25% of dividend payers in the US market (1.45%).
High Dividend: BDX's dividend (1.23%) is low compared to the top 25% of dividend payers in the US market (3.73%).
Stability and Growth of Payments
Stable Dividend: BDX's dividends per share have been stable in the past 10 years.
Growing Dividend: BDX's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its high payout ratio (110.3%), BDX's dividend payments are not well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: BDX's dividends in 3 years are forecast to be well covered by earnings (25.8% payout ratio).
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Tom Polen (46yo)
Mr. Thomas E. Polen, Jr., also known as Tom, serves as Chief Executive Officer at Becton, Dickinson and Company since January 28, 2020. Mr. Polen has been President of Becton, Dickinson and Company since A ...
CEO Compensation Analysis
Compensation vs Market: Tom's total compensation ($USD6.03M) is below average for companies of similar size in the US market ($USD10.81M).
Compensation vs Earnings: Tom's compensation has been consistent with company performance over the past year.
|Executive Chairman||7.6yrs||US$16.01m||0.091% $63.2m|
|Executive VP||6.6yrs||US$4.74m||0.0091% $6.3m|
|Executive VP & President of the Medical Segment||3.3yrs||US$4.24m||no data|
|Executive VP & President of the Life Sciences Segment||1.8yrs||US$7.05m||0.0056% $3.9m|
|VP, Controller & Chief Accounting Officer||0.3yrs||no data||0.00040% $279.1k|
|Senior VP of Corporate Finance||1.6yrs||no data||0.00078% $544.3k|
|Executive VP of Research & Development and CTO||1.7yrs||no data||no data|
|Executive VP of Global Services & Chief Information Officer||0yrs||no data||no data|
|Vice President of Investor Relations||0yrs||no data||no data|
Experienced Management: BDX's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.
|Executive Chairman||7.6yrs||US$16.01m||0.091% $63.2m|
|Lead Director||5.1yrs||US$389.68k||0.0081% $5.6m|
|Independent Director||3.4yrs||US$327.77k||0.0014% $977.0k|
|Independent Director||9.6yrs||US$350.03k||0.0061% $4.3m|
|Independent Director||17.4yrs||US$351.22k||0.011% $7.6m|
|Independent Director||5.9yrs||US$332.77k||0.0030% $2.1m|
|Independent Director||7.6yrs||US$327.77k||0.0041% $2.9m|
|Independent Director||7.1yrs||US$349.68k||0.0040% $2.8m|
|Independent Director||13.3yrs||US$351.22k||0.0077% $5.4m|
Experienced Board: BDX's board of directors are considered experienced (7.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: BDX insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Becton, Dickinson and Company's company bio, employee growth, exchange listings and data sources
- Name: Becton, Dickinson and Company
- Ticker: BDX
- Exchange: NYSE
- Founded: 1897
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$69.786b
- Shares outstanding: 271.17m
- Website: https://www.bd.com
Number of Employees
- Becton, Dickinson and Company
- 1 Becton Drive
- Franklin Lakes
- New Jersey
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|BDX||NYSE (New York Stock Exchange)||Yes||Common Stock||US||USD||Jan 1968|
|BOX||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Jan 1968|
|BDX||SWX (SIX Swiss Exchange)||Yes||Common Stock||CH||CHF||Jan 1968|
|0R19||LSE (London Stock Exchange)||Yes||Common Stock||GB||USD||Jan 1968|
|BDX *||BMV (Bolsa Mexicana de Valores)||Yes||Common Stock||MX||MXN||Jan 1968|
|BDX||WBAG (Wiener Boerse AG)||Yes||Common Stock||AT||EUR||Jan 1968|
|BOX||ETLX (Eurotlx)||Yes||Common Stock||IT||EUR||Jan 1968|
|BDXA||NYSE (New York Stock Exchange)||PFD SHS CONV A||US||USD||May 2017|
|B1DX34||BOVESPA (Bolsa de Valores de Sao Paulo)||BDR EACH 5 REPR 1 COM||BR||BRL||Jan 2020|
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company’s BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for high-throughput single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company’s BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/02/23 23:43|
|End of Day Share Price||2020/02/21 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.